{"DataElement":{"publicId":"7587877","version":"1","preferredName":"Inotuzumab Ozogamicin Agent Dose Amount","preferredDefinition":"The quantity or dosage of the agent or drug administered to the patient._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora._The amount of agent taken at one time._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","longName":"INO_AGT_DOSE_AMT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7587866","version":"1","preferredName":"Inotuzumab Ozogamicin Dose Amount","preferredDefinition":"The quantity or dosage of the agent or drug administered to the patient._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","longName":"INO_DOSE_AMOUNT","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6306958","version":"1","preferredName":"Inotuzumab Ozogamicin Dose","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.:A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","longName":"C71542:C25488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D6B8366-079B-5B9A-E053-F662850ABB56","latestVersionIndicator":"Yes","beginDate":"2018-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-30","modifiedBy":"ONEDATA","dateModified":"2018-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2440114","version":"1","preferredName":"Quantity","preferredDefinition":"Quantity; how much there is of something that you can measure.","longName":"C25256","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quantity","conceptCode":"C25256","definition":"How much there is of something that you can measure; the total amount or number.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"08704E62-EF89-4DBA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-25","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-12-25","modifiedBy":"ONEDATA","dateModified":"2005-12-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC43EB3B-AF8D-086B-E053-4EBD850A03E1","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7587871","version":"1","preferredName":"Agent Dose Inotuzumab Ozogamicin","preferredDefinition":"The amount of agent taken at one time._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","longName":"INO_AGT_DOSE","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"0.6 mg/m2","valueDescription":"0.6 mg/m2","ValueMeaning":{"publicId":"7587873","version":"1","preferredName":"0.6 mg/m2","longName":"7587873","preferredDefinition":"0.6 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC419CF1-FF5E-25B6-E053-4EBD850AAEB2","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC419CF1-FF77-25B6-E053-4EBD850AAEB2","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"},{"value":"0.5 mg/m2","valueDescription":"0.5 mg/m2","ValueMeaning":{"publicId":"7587874","version":"1","preferredName":"0.5 mg/m2","longName":"7587874","preferredDefinition":"0.5 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC419CF1-FF81-25B6-E053-4EBD850AAEB2","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC419CF1-FF9A-25B6-E053-4EBD850AAEB2","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"},{"value":"0.4 mg/m2","valueDescription":"0.4 mg/m2","ValueMeaning":{"publicId":"7587875","version":"1","preferredName":"0.4 mg/m2","longName":"7587875","preferredDefinition":"0.4 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC419CF1-FFA4-25B6-E053-4EBD850AAEB2","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC419CF1-FFBD-25B6-E053-4EBD850AAEB2","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"},{"value":"0.3 mg/m2","valueDescription":"0.3 mg/m2","ValueMeaning":{"publicId":"7587876","version":"1","preferredName":"0.3 mg/m2","longName":"7587876","preferredDefinition":"0.3 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC419CF1-FFC7-25B6-E053-4EBD850AAEB2","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC419CF1-FFE0-25B6-E053-4EBD850AAEB2","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7587870","version":"1","preferredName":"Inotuzumab Ozogamicin Dose","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.:A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","longName":"C71542:C25488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC419CF1-FF2E-25B6-E053-4EBD850AAEB2","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC419CF1-FF3F-25B6-E053-4EBD850AAEB2","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Dose Administered:","type":"Preferred Question Text","description":"Dose Administered:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC419CF1-FFEC-25B6-E053-4EBD850AAEB2","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"MAESKEB","dateModified":"2021-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}